Thrombin is a potent platelet agonist, and protease-activated receptor-1 (PAR-1) is the main thrombin receptor in human platelets and thrombin. PAR-1 antagonism has attracted interest as a potential therapeutic target to reduce atherothrombotic events in patients with atherosclerotic disease, especially coronary artery disease. In this review, the author describes the rationale of PAR-1 antagonism for the reduction of atherothrombotic events and reviews the key phase 3 trial results, with special attention to analyses in percutaneous coronary intervention patients.
Keywords: Antiplatelet therapy; Coronary artery disease; Myocardial infarction; Percutaneous coronary intervention; Protease-activated receptors; Vorapaxar.
Copyright © 2016 Elsevier Inc. All rights reserved.